Patents by Inventor Stephen E. Webber

Stephen E. Webber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090105473
    Abstract: The invention is directed to pyrro[1,2-b]pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: November 6, 2008
    Publication date: April 23, 2009
    Applicant: ANADYS PHARMACEUTICALS, INC.
    Inventors: Stephen E. Webber, Frank Ruebsam, Martin Tran, Peter Dragovich, Liansheng Li, Douglas E. Murphy, David Kucera, Zhongxiang Sun, Chinh V. Tran
  • Patent number: 7462611
    Abstract: The invention is directed to pyrro[1,2-b]pyridazinone compounds of Formula I and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus: wherein R4 is selected from Ring A is 5 or 6- membered aryl or heterocyclyl, and the remaining substituents are defined herein.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: December 9, 2008
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Frank Ruebsam, Martin Tran, Stephen E. Webber, Peter Dragovich, Liansheng Li, Douglas Murphy, David Kucera, Zhongxiang Sun, Chinh Viet Tran
  • Publication number: 20080275032
    Abstract: The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: September 11, 2007
    Publication date: November 6, 2008
    Inventors: Yuefen Zhou, Liansheng Li, Stephen E. Webber, Peter Dragovich, Douglas E. Murphy, Chinh V. Tran, Jingjing Zhao, Frank Ruebsam
  • Publication number: 20080255063
    Abstract: The invention is directed to 3-?-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.
    Type: Application
    Filed: January 17, 2008
    Publication date: October 16, 2008
    Applicant: Anadys Pharmaceuticals, Inc.
    Inventors: Devron R. Averet, Stephen E. Webber, Joseph R. Lennox, Erik J. Rueden, David Louis Clark, Alan X. Xiang
  • Patent number: 7425552
    Abstract: The invention is directed to pyridazinone compounds of Formula I and pharmaceutical compositions containing compounds of Formula I wherein R1 and R2 are independently H, alkyl, cycloalkyl, aryl, or heterocyclyl; and Ring A is 5 or 6-membered aryl or heterocyclyl. The invention also encompasses methods of using a compound of Formula I in the treatment of hepatitis C virus infections.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: September 16, 2008
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Yuefen Zhou, Liansheng Li, Stephen E. Webber
  • Publication number: 20080188466
    Abstract: The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.
    Type: Application
    Filed: September 26, 2007
    Publication date: August 7, 2008
    Applicant: ANADYS PHARMACEUTICALS, INC.
    Inventors: Peter Dragovich, Yuefen Zhou, Stephen E. Webber
  • Publication number: 20080070852
    Abstract: The invention is directed to 3-?-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.
    Type: Application
    Filed: June 7, 2004
    Publication date: March 20, 2008
    Inventors: Devron R. Averett, Stephen E. Webber, Joseph R. Lennox, Erik J. Rueden, David Louis Clark, Alan X. Xiang
  • Patent number: 7321033
    Abstract: The invention is directed to 3-?-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.
    Type: Grant
    Filed: June 7, 2004
    Date of Patent: January 22, 2008
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Devron R. Averett, Stephen E. Webber, Joseph R. Lennox, Erik J. Rueden, David Louis Clark, Alan Xin Xiang
  • Patent number: 7179918
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: February 20, 2007
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Benjamin J. Burke, Tanya M. Jewell, David J. Kucera, Maria Angelica Linton, Lennert J. Mitchell, Jr., Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Mark Barvian, Gary Bolton, Frederick Earl Boyer, Jr., Jeffrey J. Machak, Tod Holler, Sean T. Murphy, Michael Melnick, Vara Prasad Josyula
  • Patent number: 6953858
    Abstract: Compounds of the formula: where the formula variables are as defined herein, are disclosed that advantageously inhibit or block the biological activity of the HIV protease. These compounds, as well as pharmaceutical compositions containing these compounds, are useful for treating patients or hosts infected with the HIV virus. Intermediates and synthetic methods for preparing such compounds are also described.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: October 11, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Frederick Earl Boyer, Jr., Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria Angelica Linton, Jeffrey J. Machak, Lennert J. Mitchell, Jr., Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick
  • Patent number: 6924271
    Abstract: The invention is directed to 3-?-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.
    Type: Grant
    Filed: November 27, 2002
    Date of Patent: August 2, 2005
    Assignee: Anadys Pharmaceuticals, Inc.
    Inventors: Devron R. Averett, Stephen E. Webber, Joseph R. Lennox, Erik J. Rueden
  • Publication number: 20040034078
    Abstract: Compounds of formula I are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used in combination with cytotoxic agents and/or radiation.
    Type: Application
    Filed: June 4, 2003
    Publication date: February 19, 2004
    Applicant: Agouron Pharmaceuticals, Inc.
    Inventors: Donald J. Skalitzky, Stephen E. Webber, Brian Eastman
  • Publication number: 20030225071
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: June 11, 2002
    Publication date: December 4, 2003
    Inventors: Stacie S. Canan Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Fredrick E. Boyer, Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria A. Linton, Jeffrey J. Machak, Lennert J. Mitchell, Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick
  • Publication number: 20030199461
    Abstract: The invention is directed to 3-&bgr;-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and compositions, and to methods of treating diseases and disorders described herein, by administering effective amounts of such compounds.
    Type: Application
    Filed: November 27, 2002
    Publication date: October 23, 2003
    Inventors: Devron R. Averett, Stephen E. Webber, Joseph R. Lennox, Erik J. Rueden
  • Publication number: 20030153507
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: June 11, 2002
    Publication date: August 14, 2003
    Inventors: Stacie S. Canan-Koch, Therese N. Alexander, Mark Barvian, Gary Bolton, Frederick E. Boyer, Benjamin J. Burke, Tod Holler, Tanya M. Jewell, Vara Prasad Josyula, David J. Kucera, Maria A. Linton, Jeffrey J. Machak, Lennert J. Mitchell, Sean T. Murphy, Siegfried H. Reich, Donald J. Skalitzky, John H. Tatlock, Michael D. Varney, Scott C. Virgil, Stephen E. Webber, Stephen T. Worland, Michael Melnick
  • Patent number: 6362166
    Abstract: Picornaviral 3C protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of picornaviral 3C proteases. These compounds, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses. Several novel methods and intermediates can be used to prepare the novel picornaviral 3C protease inhibitors of the present invention.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: March 26, 2002
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stephen E. Webber, Peter S. Dragovich, Thomas J. Prins, Siegfried H. Reich, Thomas L. Little, Jr., Ethel S. Littlefield, Joseph T. Marakovits, Robert E. Babine, Ted M. Bleckman
  • Patent number: 6214799
    Abstract: Picornaviral 3C protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of picornaviral 3C proteases. These compounds, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses. Several novel methods and intermediates can be used to prepare the novel picornaviral 3C protease inhibitors of the present invention.
    Type: Grant
    Filed: January 7, 1999
    Date of Patent: April 10, 2001
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stephen E. Webber, Peter S. Dragovich, Thomas J. Prins, Siegfried H. Reich, Thomas L. Little, Jr., Ethel S. Littlefield, Joseph T. Marakovits, Robert E. Babine, Ted M. Bleckman
  • Patent number: 5962487
    Abstract: Picornaviral 3C protease inhibitors, obtainable by chemical synthesis, inhibit or block the biological activity of picornaviral 3C proteases. These compounds, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses. Several novel methods and intermediates can be used to prepare the novel picornaviral 3C protease inhibitors of the present invention.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: October 5, 1999
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stephen E. Webber, Peter S. Dragovich, Thomas J. Prins, Ethel S. Littlefield, Joseph T. Marakovits, Robert E. Babine
  • Patent number: 5955509
    Abstract: The present invention relates to the use of poly(vinyl N-heterocycle)-block-poly(alkylene oxide) copolymers in micelle containing pharmaceutical formulations. The copolymers advantageously respond to pH differences in the environment to which they are exposed forming micelles at higher pH values. The micelles, which comprise a therapeutic compound and a copolymer, deliver drug in a pH dependent manner.
    Type: Grant
    Filed: April 23, 1997
    Date of Patent: September 21, 1999
    Assignee: Board of Regents, The University of Texas System
    Inventors: Stephen E. Webber, Thomas J. Martin
  • Patent number: 5885996
    Abstract: Quinazoline compounds which demonstrate antiproliferative activity, such as antitumor activity, processes of preparing these compounds, pharmaceutical compositions containing these compounds, and the use of these compounds. These compounds inhibit the growth and proliferation of the cells of higher organisms and microorganisms, such as bacteria, yeasts and fungi. Preferred quinazoline compounds are capable of inhibiting the enzyme thymidylate synthase. Effects derived from the inhibition of the enzyme thymidylate synthase include those discussed above.
    Type: Grant
    Filed: September 4, 1997
    Date of Patent: March 23, 1999
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Stephen E. Webber, Ted M. Bleckman, John Attard, Terrence R. Jones, Michael D. Varney